ArticleTranslational oncology2026
Aggressive features and immune landscape of macrotrabecular hepatocellular carcinoma.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the clinical, pathological, and immune characteristics of macrotrabecular hepatocellular carcinoma (MT-HCC) to identify distinct features, evaluate prognostic significance, and explore potential therapeutic targets for MT-HCC. A total of 83 MT-HCC and 111 CV-HCC patients who underwent liver resection were included. Clinicopathological data were analyzed using statistical methods. Among these cases, immunohistochemical (IHC) staining was performed on 48 cases of massive trabecular hepatocellular carcinoma to evaluate the distribution of immune cells across different tumor regions. The Friedman test, Spearman's correlation analysis, Kaplan-Meier survival analysis, and Cox regression analysis were used to examine the relationships between immune infiltration characteristics and prognosis. MT-HCC exhibited more aggressive features, such as higher serum AFP levels (68% vs. 21%, p < 0.001), larger tumor size (7.65 cm vs. 4.47 cm, p < 0.001), and a higher frequency of vascular invasion (22% vs. 4%, p < 0.001), satellite nodules (41%vs. 16%, p < 0.001), and tumor necrosis (84% vs. 47%, p < 0.001). Survival analysis showed worse overall survival and higher recurrence rates in MT-HCC. The immune microenvironment displayed a typical "immune desert" phenotype, characterized by the spatial distribution of adaptive immune cells: sparse distribution within the tumor, enrichment at tumor margins, and enrichment adjacent to the tumor. In MT‑HCC, PD‑L1 expression was extremely low across all three tumor regions, whereas CTLA‑4 showed specific high expression at the tumor margins. Intratumoral CD8⁺ T cells exhibited a significant positive correlation with PD‑1 and CTLA‑4 (r = 0.701, P < 0.001), suggesting the dual exhaustion state of intratumoral T cells. Multivariate analysis identified cross‑regional FOXP3⁺ Treg infiltration, maximum tumor diameter, and macrovascular invasion as independent risk factors for overall survival. Conversely, peritumoral CD4⁺ T cells served as protective immune markers and were associated with reduced mortality risk in patients. The findings suggest that MT-HCC possesses invasive clinical characteristics and exhibits distinctive spatial immune heterogeneity, where immune cell distribution plays a critical role in prognosis. Targeting specific immune cell populations may offer new therapeutic strategies for MT-HCC and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.